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ABSTRACT
The U.S. Food and Drug Administration  and other regulatory bodies recently 
approved Praluent (alirocumab) and Repatha (evolocumab) for patients 
with hereditary forms of high cholesterol and those with cardiovascular 
disease. These drugs belong to a potent new class of injectable LDL-
lowering drugs known as PCSK9 inhibitors. Repatha was approved to treat 
patients with heterozygous familial hypercholesterolemia (HeFH) and 
patients with the rarer homozygous (HoFH) form of the disease. It was also 
approved for patients with cardiovascular disease including heart attack 
or stroke, who require additional cholesterol lowering. The scope of the 
approval was similar to the approval given to the Regeneron drug, Praluent 
(alirocumab), which was approved for patients with cardiovascular disease 
and those with HeFH.
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INTRODUCTION
Statins have been the first-line drugs for lower-
ing cholesterol  since the late 1980s. They’ve been 
shown to prevent repeat heart attacks in people 
who have already had one and first heart attacks in 
a wide range of at-risk individuals. In about one in 
five people, though, a statin doesn’t lower choles-
terol enough. Adding a second drug that lowers 
cholesterol by a different mechanism doesn’t always 
help. And some people can’t take a statin because 
of side effects like muscle pain, liver damage, or the 
development of diabetes.1
The U.S. Food and Drug Administration  and 
other regulatory bodies recently approved Praluent 
(alirocumab) and Repatha (evolocumab) for 
patients with hereditary forms of high choles-
terol and those with cardiovascular disease. These 
drugs belong to a potent new class of injectable 
LDL-lowering drugs known as PCSK9 inhibitors.
Repatha was approved to treat patients with 
heterozygous familial hypercholesterolemia 
(HeFH) and patients with the rarer homozygous 
(HoFH) form of the disease. It was also approved for 
patients with cardiovascular disease including heart 
attack or stroke, who require additional cholesterol 
lowering. The scope of the approval was similar to 
the approval given to the Regeneron drug, Praluent 
(alirocumab), which was approved for patients with 
cardiovascular disease and those with HeFH. The 
drugs are expected to generate more than $2 billion 
a year each in sales by 2020, according to Thomson 
Reuters data.
Praluent is given every other week by injection 
in doses of 75 mg or 150 mg. Both doses of the 
drug will be priced wholesale at $1,120 for a 28-day 
supply, or roughly $14,560 a year. After rebates, 
analysts expect the drug to cost about $12,400 a 
year. Repatha is given as a 140 mg injection every 
other week or as a monthly injection of 420 mg. 
Amgen said the wholesale cost of the drug will be 
$14,100 a year for the every other week injection. 
The product will be available next week.
PCSK9 INHIBITORS
Monoclonal antibodies, target and inactivate a 
specific protein in the liver. Knocking out this 
protein, called proprotein convertase subtilisin 
kexin 9, dramatically reduces the amount of harm-
ful LDL cholesterol circulating in the bloodstream. 
Lower LDL translates into healthier arteries and 
fewer heart attacks, strokes, and other problems 
related to cholesterol-clogged arteries. Proprotein 
convertase subtilisin/kexin type 9 (PCSK9) is an 
enzyme that plays an important role in lipid metab-
olism by modulating the density of LDL choles-
terol receptors in multiple organs. The enzyme is 
synthesized in the nucleus, and after intramolecular 
autocatalytic cleavage of its N-terminal prosegment 
in the endoplasmic reticulum, it is secreted from 
hepatocytes, where it binds to the surrounding LDL 
cholesterol receptors. The complex is then subject to 
endocytosis and degradation of its entire structure 
in lysosomes.7 This physiologic function leads to an 
inverse relationship between the level of PCSK9 in 
the blood and the number of LDL receptors; inhibi-
tion of PCSK9 prevents LDL receptor degradation 
within lysosomes and preserves receptor recycling 
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to the hepatocyte surface. Each receptor normally 
recycles approximately 150 times. Thus, mono-
clonal antibody binding and inhibition of PCSK9 
prevents PCSK9 binding to the LDL cholesterol–
LDL receptor complex and subsequent lysosomal 
degradation of the LDL receptor. The LDL-receptor 
recycling is preserved, with a consequent increase 
in receptor density on the hepatocyte surface and 
LDL cholesterol clearance.
How do they work
PCSK9 is predominantly produced in the liver.1-3 
PCSK9 binds to the low density lipoprotein recep-
tor (LDL-R) on the surface of hepatocytes, leading 
to the degradation of the LDL-R and higher plasma 
LDL-cholesterol (LDL-C) levels.4,5 Antibodies to 
PCSK9 interfere with its binding of the LDL-R lead-
ing to higher hepatic LDL-R expression and lower 
plasma LDL-C levels (figure 1).21
There are several strategies to lower free plasma 
PCSK9, including antisense, silencing ribonucleic 
acid (RNA), and monoclonal antibody strategies. 
PCSK9-antibodies are the first of these thera-
pies approved for clinical use. These antibodies 
are specific for PCSK9 and do not bind to other 
members of the PCSK enzyme family.7,8
Alirocumab and evolocumab are fully human-
ized monoclonal antibodies that bind free plasma 
PCSK9, promoting degradation of this enzyme.9-12 
As a result, less free PCSK9 is available in plasma 
to bind to LDL-R. This results in a higher fraction 
of LDL-R recycling towards the hepatocyte surface. 
As a direct consequence, the liver has the capacity 
to remove more LDL-C from the circulation, result-
ing in lower LDL-C plasma levels.
Evidence
Results from seven multi-centre, double-blind, 
placebo- and/or active (ezetimibe)-controlled, 
randomized phase 3 trials evaluating evolocumab 
in more than 4,500 patients have been reported.13-19 
The co-primary outcomes of five trials were the per 
cent change from baseline in LDL-C at 12 weeks 
and averaged between weeks 10 and 12 (to more 
accurately reflect average LDL-C reduction over the 
entire dosing interval).13-15,19 This bulletin reports 
data for the treatment difference at 12 weeks. The 
primary outcomes for the other two trials were per 
cent change from baseline in LDL-C at 12 weeks41 
or at 52 weeks.20
Five of the trials evaluated evolocumab adminis-
tered at a dose of 140 mg every two weeks or 420 mg 
every month in patients with primary hyper-
cholesterolemia (non-familial and heterozygous 
familial hypercholesterolemia) and mixed dyslip-
idemia.13-15,17,18 A heterogeneous population was 
assessed in these trials, in which approximately 20% 
had a history of coronary heart disease and fewer 
than 50% of participants were considered to be at 
moderate to high cardiovascular risk at baseline. One 
trial evaluated evolocumab administered at a dose of 
420 mg every month in patients with homozygous 
familial hypercholesterolemia.19 Approximately 
43% of these patients had established coronary 
artery disease. One trial evaluated evolocumab at 
a dose of 420 mg every month in patients with a 
range of cardiovascular risks.15 The majority (64%) 
of participants in this trial were at low or moderate 
cardiovascular risk. Patients enrolled in the evolo-
cumab phase 3 clinical program (who were not 
considered statin intolerant) were not all required 
to be taking maximally tolerated statin background 
therapy prior to the addition of evolocumab, which 
may not be well aligned with the proposed future 
use of evolocumab in clinical practice.
Adverse Effects
Overall, patients treated with PCSK9 inhibitors 
had higher rates of nonspecific side effects, such 
as arthralgia, headache, limb pain and fatigue, 
compared with placebo-treated patients. Adverse 
events were reported in 69 percent of people taking 
evolocumab in the clinical trials. Injection-site 
swelling or rash, limb pain, and fatigue were some 
of the reported side effects. Less than one percent 
reported mental confusion, difficulty focusing, or 
other neurocognitive issues.8
In the alirocumab trials, adverse events were 
reported in 81 percent of participants taking the 
drug. These included injection-site reactions, 
muscle pain, and eye-related events. Slightly 
more than 1 percent of participants reported Figure 1  Mechanism of PCSK9 inhibition (Image reproduced from Ref. 21)
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neurocognitive adverse events. These included 
memory impairment and confusion.20
However, clinicians were most concerned about 
neurocognitive events. Overall, 1% to 1½% of 
patients experienced treatment-related neurocog-
nitive effects, mainly confusion and some memory 
loss. However, it’s important to note that the neuro-
cognitive issues were not related to the amount of 
LDL-C decrease.
CONCLUDING REMARKS
PCSK9 inhibitor monoclonal antibodies have the 
potential to fill an important treatment gap in 
patients with harder-to-treat hypercholesterolemia. 
Results from trials, which mainly focus on surrogate 
markers of cardiovascular outcomes, showed that 
PCSK9 inhibitor monoclonal antibodies produce 
statistically significant reductions in LDL-C regard-
less of background lipid-lowering therapy. Based on 
the relatively short-term evidence that is currently 
available, these drugs appear to be safe, although 
the FDA has identified a potential signal for neuro-
cognitive adverse effects. Given that cardiovascular 
disease is still one of the most important causes of 
death in Canada, despite the availability of statins 
for 25 years, PCSK9 inhibitor monoclonal antibod-
ies are expected to be rapidly adopted if approved, 
particularly for patients with harder-to-treat hyper-
cholesterolemia. However, long-term safety and 
the effect on cardiovascular outcomes remain to 
be established. Findings from long-term outcomes 
trials will not be available until 2017 or 2018.
Given the potential broad clinical use of this new 
drug class, the high price, and the long time frame 
required for the introduction of less expensive subse-
quent entry biologics, the introduction of PCSK9 
inhibitor monoclonal antibodies may potentially 
have a substantial budgetary impact on the Canadian 
health care system. Careful patient selection will 
be necessary. The requirement to  self-administer 
the drug subcutaneously may also impact long-
term patient acceptability and adherence. In order 
to determine the clinical impact and value of this 
new drug class on the potentially broad and diverse 
population of patients with  difficult-to-treat hyper-
cholesterolemia, the long-term safety, efficacy, and 
cost-effectiveness of PCSK9 inhibitor monoclonal 
antibodies need to be clarified.22
DISCLAIMER
This article is based on a report by Canadian Agency 
for Drugs and Technologies in Health.22
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